Pharma Execs Can't Duck Prosecutors With Off-Label Ruling
Pharmaceutical company executives hopeful that the U.S. Food and Drug Administration might refrain from prosecuting individuals for their company's off-label marketing misdeeds, after a landmark Second Circuit decision backed a sales...To view the full article, register now.
Already a subscriber? Click here to view full article